19th January 2017
Nuformix is pleased to announce it has today received the grant of its NXP002 patent in Europe. Nuformix is pursuing global patent coverage for NXP002 asset, which offers multiple options for future development and this is the second major territory in which the broad patent has been granted. Nuformix Chief Executive Officer, Dr Dan Gooding, said: “NXP002 is an incredibly exciting asset for Nuformix so we are delighted to have secured substance-of- matter protection in a second critical territory and set further precedent for future European filings.”